Pharmacokinetics of 5-Ht6 Receptor Ligands

International Review of Neurobiology

Volumn 94, Issue C, 2010, Pages 153-172

  Mancinelli, Angelo ^a  

^a Sigma Tau SpA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

3 PHENYLSULFONYL 8 (1 PIPERAZINYL)QUINOLINE; 4 AMINO N [2,6 BIS(METHYLAMINO) 4 PYRIDINYL]BENZENESULFONAMIDE; 4 AMINO N [2,6 BIS(METHYLAMINO) 4 PYRIMIDINYL]BENZENESULFONAMIDE; 5 CHLORO N [4 METHOXY 3 (1 PIPERAZINYL)PHENYL] 3 METHYL 2 BENZOTHIOPHENESULFONAMIDE; BVT 74316; DRUG METABOLITE; GLYCOPROTEIN P; GSK 215083; LIGAND; LY 483518; N (3,5 DICHLORO 2 METHOXYPHENYL) 4 METHOXY 3 (1 PIPERAZINYL)BENZENESULFONAMIDE; PRX 07034; RADIOLIGAND; SAM 531; SB 357134; SEROTONIN 6 ANTAGONIST; SEROTONIN 6 RECEPTOR; SEROTONIN 6 RECEPTOR AGONIST; SGS 518; ST 1936; SUVN 502; SUVN 623; TOLYLPIPERIDINE; UNCLASSIFIED DRUG; VERAPAMIL; WAY 181187; WAY 262531;

ALZHEIMER DISEASE; AREA UNDER THE CURVE; BLOOD BRAIN BARRIER; BOOK; CLINICAL TRIAL; COGNITIVE DEFECT; DIFFUSION; DISTRIBUTION VOLUME; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; DRUG CEREBROSPINAL FLUID LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG METABOLISM; DRUG PENETRATION; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG TRANSFORMATION; DRUG TRANSPORT; HUMAN; HYDROGEN BOND; HYDROGEN BOND DONOR; ISOTOPE LABELING; LIPOPHILICITY; LIVER MICROSOME METABOLISM; MAXIMUM PLASMA CONCENTRATION; MOLECULAR WEIGHT; MULTIPLE DRUG DOSE; NONHUMAN; OBSESSIVE COMPULSIVE DISORDER; PARTITION COEFFICIENT; PHYSICAL PARAMETERS; POLAR SURFACE AREA; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; RECEPTOR OCCUPANCY; SINGLE DRUG DOSE; STRUCTURE ACTIVITY RELATION; TIME TO MAXIMUM PLASMA CONCENTRATION; TISSUE DISTRIBUTION;

EID: 78449263364     PISSN: 00747742     EISSN: None     Source Type: Book Series    
DOI: 10.1016/B978-0-12-384976-2.00007-1     Document Type: Chapter

References (47)

1. Abraham, R., Shanmuganathan, D., Jayarajan, P., Dokania, M. K., Kandikere, V., Bhyrapuneni, G., Saralaya, R., Daulatabad, A., Shinde, A., Ahmad, I., Reddy, V., and Nirogi, R. (2009). SUVN-623: a 5-HT6 antagonist in animal models of cognition. Neuroscience 2009, Society for Neuroscience Annual Meeting, Chicago, USA, October 17-21. Post.FF109.
2. Bedini, A., Tomasi, G., Spadoni, G., Tarzia, G., Minetti, P., Di Cesare, M. A., and Carminati, P. (2005). 2-5-Disubstituted tryptamines as selective serotonin 5-HT6 receptor agonists. 2nd Italian Swiss Meeting Medicinal Chemistry, Modena, Italy, September, 12-16, Abstract p. 98.
3. Bös M., Sleight A.J., Godel T., Martin J.R., Riemer C., Stadler H. 5-HT6 receptor antagonists: lead optimisation and biological evaluation of N-aryl and N-heteroaryl 4-amino-benzene sulfonamides. Eur. J. Med. Chem. 2001, 36:165-178.
4. Bourson A., Boess F.G., Bös M., Sleight A.J. Involvement of 5-HT6 receptors in nigro-striatal function in rodents. Br. J. Pharmacol. 1998, 130:1606-1612.
5. Bromidge S.M., Brown A.M., Clarke S.E., Dodgson K., Gager T., Grassam H.L., Jeffrey P.M., Joiner G.F., King F.D., Middlemiss D.N., Moss S.F., Newman H., Riley G., Routledge C., Wyman P. 5-chloro-N-(4-methoxy-3-piperazin-1-yl-phenyl)-3-methyl-2-benzothiophene sulfonamide (SB-271046): a potent, selective, and orally bioavailable 5-HT6 receptor antagonist. J. Med. Chem. 1999, 42:202-205.
6. Bromidge S.M., Clarke S.E., Gager T., Griffith K., Jeffrey P., Jennings A.J., Joiner G.F., King F.D., Lovell P.J., Moss S.F., Newman H., Riley G., Rogers D., Routledge C., Serafinowska H., Smith D.R. Phenyl benzenesulfonamides are novel and selective 5-HT6 antagonists: identification of N-(2,5-dibromo-3-fluorophenyl)-4-methoxy-3-piperazin-1-ylbenzenesulfonam ide (SB-357134). Bioorg. Med. Chem. Lett. 2001, 11:55-58.
7. Campiani G., Cappelli A., Nacci V., Anzini M., Vomero S., Hamon M., Cagnotto A., Fracasso C., Uboldi C., Caccia S., Consolo S., Mennini T. Novel and highly potent 5-HT3 receptor agonist based on a pyrroloquinoxaline structure. J. Med. Chem. 1997, 40:3670-3678.
8. Cole D.C., Stock J.R., Lennox W.J., Bernotas R.C., Ellingboe J.W., Boikess S., Coupet J., Smith D.L., Leung L., Zhang G.M., Feng X., Kelly M.F., Galante R., Huang P., Dawson L.A., Marquis K., Rosenzweig-Lipson S., Beyer C.E., Schechter L.E. Discovery of N1-(6-chloroimidazol[2,1-b][1,3]-thiazole-5-sulfonyl)tryptamine as a potent, selective, and orally active 5-HT6 receptor agonist. J. Med. Chem. 2007, 50:5535-5538.
9. Davis B., Morris T. Commentary: physiological parameters in laboratory animals and humans. Pharm. Res. 1993, 10:1093-1095.
10. Elmquist W.F., Sawchuk R.J. Application of microdialysis in pharmacokinetic studies. Pharm. Res. 1997, 14:267-288.
11. Fuller R.W., Snoddy H.D., Perry K.W. Tissue distribution, metabolism and effects of bufotenine administered to rats. Neuropharmacology 1995, 34:799-804.
12. Geldenhuys W.J., Van der Schyf C.J. The serotonin 5-HT6 receptor: a viable drug target for treating cognitive deficits in Alzheimer's disease. Expert Rev. Neurother. 2009, 9:1073-1085.
13. Glennon R.A. Higher-end serotonin receptors: 5-HT5, 5-HT6, and 5-HT7. J. Med. Chem. 2003, 46:2795-2812.
14. Glennon R.A., Lee M., Rangisetty B., Dukat M., Roth B.L., Savage J.E., McBride A., Rause L., Hufeisen S., Lee D.K.H. 2-Substituted tryptamines: agents with selectivity for 5-HT6 serotonin receptors. J. Med. Chem. 2000, 43:1011-1018.
15. Hammarlund-Udenaes M., Fridén M., Syvänen S., Gupta A. On the rate and extent of drug delivery to the brain. Pharm. Res. 2008, 25:1737-1750.
16. Hirst W.D., Minton J.A.L., Bromidge S.M., Moss S.F., Latter A.J., Riley G., Routledge C., Middlemiss D.N., Price G.W. Characterization of [125I]-SB-258585 binding to human recombinant and native 5-HT6 receptors in rat, pig and human brain tissue. Br. J. Pharmacol. 2000, 130:1597-1605.
17. Hirst W.D., Stean T.O., Rogers D.C., Sunter D., Pugh P., Moss S.F., Bromidge S.M., Riley G., Smith D.R., Bartlett S., Heidbreder C.A., Atkins A.R., Lacroix L.P., Dawson L.A., Foley A.G., Regan C.M., Upton N. SB-399885 is a potent, selective 5-HT6 receptor antagonist with cognitive enhancing properties in aged rat water maze and novel object recognition models. Eur. J. Pharmacol. 2006, 553:109-119.
18. Hitchcock S.A., Pennington L.D. Structure-brain exposure relationships. J. Med. Chem. 2006, 49:7559-7583.
19. Holenz J., Pauwels P.J., Diaz J.L., Merc R., Codony X., Buschmann H. Medicinal chemistry strategies to 5-HT6 receptor ligands as potential cognitive enhancers and antiobesity agents. Drug Discov. Today 2006, 11:283-299.
20. Kalberer F., Kreis W., Rutschmann J. The fate of psilocin in rat. Biochem. Pharmacol. 1962, 11:261-269.
21. Kelly J. Pharmacokinetic Considerations: Absorption, Distribution, Metabolism and Elimination: From Principles of CNS Drug Development: From Test Tube to Patient 2009, John Wiley & Sons Ltd, Chichester, UK, 127-285.
22. Kohen R., Metcalf M.A., Khan N., Druck T., Huebner K., Lachowicz J.E., Meltzer H.Y., Sibley D.R., Roth B.L., Hamblin M.W. Cloning, characterization, and chromosomal localization of a human 5-HT6 serotonin receptor. J. Neurochem. 1996, 66:47-56.
23. Liu X., Chen C., Smith B.J. Progress in brain penetration evaluation in drug discovery and development. J. Pharmacol. Exp. Ther. 2008, 325:349-356.
24. Mancinelli, A., Brogin, G., Pace, S., and Borsini, F. (2010). Pharmacokinetics and brain disposition of ST1936, a potent 5-HT6 recepotor agonist, in rat. 9th International Meeting of the International Society for the Study of Xenobiotics (ISSX), Istanbul (Turkey), September 4-8, Abstract 109.
25. Martarello L., Cunningham V., Matthews J.C., Rabiner E., Jakobsen S., Gee A. Radiolabelling and in vivo evaluation of [11C]GSK215083 as potential PET radioligand for the 5-HT6 receptor in the porcine brain. J. Cereb. Blood Flow Metab. 2005, 25:S598.
26. Martarello L., Parker C., Cunningham V., Searle G., Rabiner E., Gee A., Davy M., Laruelle M. First evaluation in humans of [11C]GSK215083 as a probe to image the 5-HT6 receptors. J. Nucl. Med. 2008, 49(Suppl. 1):79.
27. Monsma F.J., Shen Y., Ward R.P., Hamblin M.W., Sibley D.R. Cloning and expression of a novel serotonin receptor with high affinity for tricyclic psychotropic drugs. Mol. Pharmacol. 1993, 43:320-327.
28. Nirogi, R., Kandikere, V., Mudigonda, K., Bhyrapuneni, G., and Jasti, V. (2009). Human phase-1 multiple ascending dose (MAD) study-safety, tolerability and pharmacokinetics of SUVN-502, a 5-HT6 receptor antagonist. Alzheimer's Association's International Conference on Alzheimer 's Disease (ICAD 2009), Vienna, July 11-16. Abstracts pp. P1-252 and P1-253.
29. Parker C.A., Cunningham V.J., Martarello l., Rabiner E.A., Searle G.E., Gee A.D., Davy M., Johnson C.N., Ahmed M., Gunn R.N., Laurelle M. Evaluation of the novel 5-HT6 receptor radioligand, [11C]GSK215083 in human. NeuroImage 2008, 41(Suppl. 2):T20.
30. Reavill C., Rogers D.C. The therapeutic potential of 5-HT6 receptor antagonists. Curr. Opin. Investig. Drugs 2001, 2:104-109.
31. Romero G., Sanchez E., Pujol M., Perez P., Codony X., Holenz J., Buschmann H., Puwels P.J. Efficacy of selective 5-HT6 receptor ligands determined by monitoring 5-HT6 receptor-mediated cAMP signaling pathways. Br. J. Pharmacol. 2006, 148:1133-1143.
32. Roth B.L., Craigo S.C., Choudhary M.S., Uluier A., Monsma F.J., Shen Y., Meltzer H.Y., Sibley D.R. Binding to typical and atypical antipsychotic agents to 5-hydroxytryptamine-6 and 5-hydroxytryptamine-7 receptors. J. Pharmacol. Exp. Ther. 1994, 268:1403-1410.
33. Routledge C., Bromidge S.M., Moss S.F., Price G.W., Hirst W., Newman H., Riley G., Gager T., Stean T., Upton N., Clarke S.E., Brown A.M., Meddlemiss D.N. Characterization of SB-271046: a potent, selective and orally active 5-HT6 receptor antagonist. Br. J. Pharmacol. 2000, 130:1606-1612.
34. Ruat M., Traiffort E., Arrang J.M., Tardivel-Lacombe J., Diaz J., Leurs R., Swartz J.C. A novel serotonin (5-HT6) receptor: molecular cloning, localisation and stimulation of cAMP accumulation. Biochem. Biophys. Res. Commun. 1993, 193:269-276.
35. Russell M.G.N., Baker R.J., Barden L., Beer M.S., Bristow L., Broughton H.B., Knowles M., McAllister G., Patel S., Castro J.L. N-Arylsulfonylindole derivatives as serotonin HT6 receptor ligands. J. Med. Chem. 2001, 44:3881-3895.
36. Schechter L.E., Lin Q., Smith D.L., Zhang G., Shan Q., Platt B., Brandt M.R., Dawson L.A., Cole D., Bernotas R., Robichaud A., Rosenzweig-Lipson S., Beyer C. Neuropharmacological profile of novel and selective 5-HT6 receptor agonists: Way-181187 and Way-208466. Neuropsychopharmacology 2008, 33:1323-1335.
37. Singer M.J., Wilson M.W., Johnson P.D., Graham S.R., Cooke L.W., Roof R.L., Boxer P.A., Gold L.H., Meltzer L.T., Janssen A., Roush N., Campbell J.E., Su T.Z., Hurst S.I., Stoner C.L., Schwartz J.B. Synthesis and SAR of tolylamine 5-HT6 antagonists. Bioorg. Med. Chem. Lett. 2009, 19:2409-2412.
38. Sleight A.J., Boess F.G., Bös M., Levet-Trafit B., Riemer C., Bourson A. Characterization of Ro 04-6790 and Ro 63-0563: potent and selective antagonists at human and rat of 5-HT6 receptors. Br. J. Pharmacol. 1998, 124:556-562.
39. Stean T.O., Hirst W.D., Thomas D.R., Price G.W., Rogers D., Riley G., Bromidge S.M., Serafinowska H.T., Smith D.R., Bartlett S., Deeks N., Duxon M., Upton N. Pharmacological profile of SB-357134: a potent, selective, brain penetrant, and orally active 5-HT6 receptor antagonist. Pharmacol. Biochem. Behav. 2002, 71:645-654.
40. Tang S., Verdurand M., Joseph B., Lemoine L., Daoust A., Billard T., Fournet G., Le Bars D., Zimmer L. Synthesis and biological evaluation in rat and cat of [18F]12ST05 as a potential 5-HT6 PET radioligand. Nucl. Med. Biol. 2007, 34:995-1002.
41. Unsworth C.D., Molinoff P.B. Characterization of a 5-hydroxy-tryptamine receptor in mouse neuroblastoma N18TG2 cells. J. Pharmacol. Exp. Ther. 1994, 269:246-255.
42. Upton N., Chuang T.T., Hunter A.J., Virley D.J. 5-HT6 receptor antagonists as novel cognitive enhancing agents for Alzheimer's disease. Neurotherapeutics 2008, 5:458-469.
43. Valentini V., De Luca M.A., Borsini F., Frau R., Di Chiara G. Behav. Pharmacol. 2009, 20(Special issue 1):45. S36.
44. Verbeuren T.J. 5-Hydroxytryptamine: distribution, synthesis, metabolism, release, uptake and passage across body membranes in cardiovascular tissues, including blood brain barrier. 5-Hydroxytryptamine Mechanisms in Primary Headache 1992, 29-39. Raven Press, New York. J. Olsen, P.R. Saxena (Eds.).
45. Willmann J.K., van Bruggen N., Dinkelborg L.M., Gambhir S.S. Molecular imaging in drug development. Nat. Rev. Drug Discov. 2008, 7:591-607.
46. Yu A.M. Indolealkylamines: biotransformations and potential drug-drug interactions. AAPS J. 2008, 10:242-253.
47. Zhou P., Yan Y., Bernotas R., Harrison B.L., Huryn D., Robichaud A.J., Zhang G.M., Smith D.L., Schechter L.E. 4-(2-Aminoethoxy)-N-(phenylsulfonyl)indoles as novel 5-HT6 receptor ligands. Bioorg. Med. Chem. Lett. 2005, 15:1393-1396.